Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Role of PSMA-PET Expands in the Treatment of Prostate Cancer

November 11th 2022

David Albala, MD, discusses integrating PSMA-PET imaging into the clinic and determining which patients with prostate cancer are prime candidates.

Shore Unpacks Treatment Advances for Patients With Urologic Cancers

November 11th 2022

Neal Shore, MD, FACS, highlights the effect of genetic testing on the treatment paradigm of prostate cancer and the evolving treatment landscape for metastatic castration resistant prostate cancer.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

FDA Greenlights Leuprolide Acetate Injection for Palliative Treatment in Advanced Prostate Cancer

November 2nd 2022

The FDA has approved leuprolide acetate injection for use in the palliative treatment of patients with advanced prostate cancer.

Dr. Berg on the Role of the PEACE-1 and ARASENS Trials in Expanding mHSPC Treatment

November 1st 2022

Stephanie Berg, DO, discusses two key clinical trials that have advanced the standard of care in metastatic hormone-sensitive prostate cancer.

Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and Classification

October 31st 2022

Christopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?

October 28th 2022

PARP inhibitors have emerged as agents that generate improved oncological outcomes in select patient populations with metastatic castration-resistant prostate cancer.

Darolutamide Combination Improves OS vs Placebo in Black Patients With mHSPC

October 28th 2022

Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.

Radiation Plus Intermittent Hormone Therapy Improves PFS in Oligometastatic Prostate Cancer

October 27th 2022

A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.

Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer

October 24th 2022

The combination of cediranib and olaparib significantly improved radiographic progression-free survival compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer.

Dr. Aggarwal on ADT Intensification in Biochemically Relapsed Prostate Cancer

October 20th 2022

Rahul Aggarwal, MD, discusses the rationale for investigating androgen deprivation therapy intensification in biochemically relapsed prostate cancer.

Dr. Shore on Future Clinical Research Focuses in Prostate Cancer

October 14th 2022

Neal Shore MD, FACS, discusses future clinical research focuses in prostate cancer.

Pluvicto Receives Support for European Approval in PSMA-Positive mCRPC

October 14th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of Lutetium 177 vipivotide tetraxetan in combination with androgen deprivation therapy with or without androgen receptor pathway inhibition for the treatment of adult patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer who have been treated with AR pathway inhibition and taxane-based chemotherapy.

Novel AR-Targeted Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Which One to Choose

October 5th 2022

Advances in the understanding of the genomics and biological functions of prostate cancer have resulted in the emergence of several new classes of agents that have improved outcomes in men with prostate cancer, including metastatic hormone-sensitive prostate cancer.

Talazoparib/Enzalutamide Combo Meets rPFS End Point in Untreated Metastatic CRPC

October 4th 2022

The addition of talazoparib to enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs enzalutamide plus placebo in previously untreated patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.

Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC

October 3rd 2022

Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.

FDA Accepts NDA for 18F-rhPSMA-7.3 as Diagnostic Imaging Tool in Prostate Cancer

September 29th 2022

The FDA has accepted for review a new drug application for 18F-rhPSMA-7.3, an investigational radiohybrid PSMA-targeted PET imaging agent for diagnostic imaging of prostate cancer, according to an announcement from Blue Earth Diagnostics.

AZD4635 Plus Durvalumab or Oleclumab Has Minimal Clinical Activity in mCRPC

September 26th 2022

The addition of AZD4635 to durvalumab or oleclumab did not elicit significant responses in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Dr. Moon on the Future of Care in Prostate Cancer

September 21st 2022

Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.

Exploring High-Intensity Focused Ultrasound as an Organ-Sparing Option for Prostate Cancer

September 21st 2022

The definitive treatment of prostate cancer has historically relied on whole-gland treatment.